About Ultivue
Ultivue is a company based in Cambridge (United States) founded in 2015. Ultivue has raised $105.23 million across 5 funding rounds from investors including Applied Materials, Arch Venture Partners and Ally Bridge Group. Ultivue offers products and services including OmniVUE, U-VUE, InSituPlex, and STARVUE. Ultivue operates in a competitive market with competitors including Personalis, OncoDNA, Strata Oncology, RootPath Genomics and Precede, among others.
- Headquarter Cambridge, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Ultivue, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$105.23 M (USD)
in 5 rounds
-
Latest Funding Round
$3.32 M (USD), Series D
Jul 11, 2024
-
Investors
Applied Materials
& 8 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Ultivue
Ultivue offers a comprehensive portfolio of products and services, including OmniVUE, U-VUE, InSituPlex, and STARVUE.
Offers core biomarkers for cancer research analysis
Provides customized biomarker solutions for research needs
Enables ultrasensitive detection of biomarkers in tissues
Delivers AI-enhanced spatial phenomics for tumor microenvironments
People of Ultivue
Unlock access to complete
Unlock access to complete
Funding Insights of Ultivue
Ultivue has successfully raised a total of $105.23M across 5 strategic funding rounds. The most recent funding activity was a Series D round of $3.32 million completed in July 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Ultivue
Ultivue has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include Applied Materials, Arch Venture Partners and Ally Bridge Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity and hedge fund investments in healthcare are managed.
|
Locked | Locked | Locked | |
|
Investment management services are provided focusing on healthcare innovation.
|
Locked | Locked | Locked | |
|
Venture capital firm focused on multiple sectors
|
Locked | Locked | Locked |
Investor details for Ultivue
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Ultivue
Investment portfolio details for Ultivue
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Ultivue
Detailed financials for Ultivue
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Ultivue Comparisons
Peer comparison for Ultivue
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Ultivue
Ultivue operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Personalis, OncoDNA, Strata Oncology, RootPath Genomics and Precede, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Genomic sequencing and diagnosis software is provided for healthcare.
|
|
| Locked | Locked | Locked |
Genomic and theranostic services for oncology precision medicine are delivered.
|
|
| Locked | Locked | Locked |
Genetic sequencing is provided for late-stage cancer patients.
|
|
| Locked | Locked | Locked |
Immunotherapy platform is developed for personalized cancer treatment.
|
|
| Locked | Locked | Locked |
Circulating chromatin is profiled via liquid-biopsy platform for cancer diagnosis.
|
Detailed competitors of Ultivue
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Ultivue
Complete news archive for Ultivue
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ultivue
Ultivue was founded in 2015.
Ultivue is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Ultivue is a funded company, having raised a total of $105.23M across 5 funding rounds to date.
Ultivue was founded in 2015 and is based in Cambridge, United States, within the biotechnology sector focused on oncology. Biomarker panels are created to assess the immune landscape, supporting precision therapies. Key products include FixVUE, FlexVUE, and U-VUE. Multiplex immunofluorescence services are delivered using proprietary InSituPlex technology, which involves DNA-barcoding and antibody staining for tissue analysis.
Ultivue's top competitors include Personalis, OncoDNA and ACT Genomics.
Ultivue offers OmniVUE, U-VUE, InSituPlex, and STARVUE.
Ultivue has 9 investors. Key investors include Applied Materials, Arch Venture Partners, Ally Bridge Group, Pura Vida, and Tao Capital Partners.